Victory Capital Management Inc. Sells 7,441 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Victory Capital Management Inc. cut its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 113,701 shares of the biopharmaceutical company’s stock after selling 7,441 shares during the quarter. Victory Capital Management Inc.’s holdings in Alexion Pharmaceuticals were worth $13,597,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ALXN. Jennison Associates LLC increased its position in shares of Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares during the last quarter. Assenagon Asset Management S.A. increased its position in shares of Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after purchasing an additional 864,967 shares during the last quarter. Alkeon Capital Management LLC bought a new position in shares of Alexion Pharmaceuticals during the 3rd quarter valued at about $70,145,000. Wells Fargo & Company MN increased its position in shares of Alexion Pharmaceuticals by 32.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its position in shares of Alexion Pharmaceuticals by 46.7% during the 3rd quarter. Pictet Asset Management Ltd. now owns 1,126,275 shares of the biopharmaceutical company’s stock valued at $158,005,000 after purchasing an additional 358,695 shares during the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

ALXN has been the subject of several analyst reports. Zacks Investment Research upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 target price for the company in a report on Tuesday, October 31st. BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Citigroup dropped their target price on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a report on Friday, February 9th. SunTrust Banks set a $172.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Monday. Finally, Stifel Nicolaus restated a “buy” rating and set a $151.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and twenty-one have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $152.77.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) opened at $123.20 on Thursday. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. The firm has a market capitalization of $27,310.00, a P/E ratio of 62.54, a price-to-earnings-growth ratio of 1.08 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 1.36% and a net margin of 3.33%. The business had revenue of $909.70 million during the quarter, compared to analysts’ expectations of $880.38 million. During the same quarter last year, the business posted $1.26 EPS. The business’s revenue was up 9.5% on a year-over-year basis. sell-side analysts forecast that Alexion Pharmaceuticals, Inc. will post 5.87 earnings per share for the current year.

In other Alexion Pharmaceuticals news, CFO Paul J. Clancy sold 6,079 shares of the stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $116.31, for a total value of $707,048.49. Following the completion of the sale, the chief financial officer now owns 95,093 shares in the company, valued at approximately $11,060,266.83. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ludwig Hantson sold 13,245 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $116.31, for a total value of $1,540,525.95. Following the completion of the transaction, the chief executive officer now owns 131,425 shares of the company’s stock, valued at approximately $15,286,041.75. The disclosure for this sale can be found here. In the last quarter, insiders sold 28,930 shares of company stock valued at $3,378,199. Company insiders own 4.35% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2018/02/15/victory-capital-management-inc-sells-7441-shares-of-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply